ScreenerHero

MDXGMiMedx Group, Inc.

NAS · US · Healthcare · Biotechnology · mimedx.com
4.330USD-2.70%Mkt Cap: 631.14M $P/E: 108.25

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
MiMedx (MDXG) Q2 2026 Earnings Call Transcript

Surgical revenue grew 15% as wound care stabilized ahead of $350M Sanara deal.

Motley Fool
MiMedx Group, Inc. Q2 2026 Earnings Call Summary

Moby summary of MiMedx Group, Inc.'s Q2 2026 earnings call

Moby
MiMedx Group Inc (MDXG) (Q2 2026) Earnings Call Highlights: Surgical Growth and Transformative ...

MiMedx reports strong surgical momentum and a transformational acquisition, while navigating a challenging wound care market with early signs of stabilization.

GuruFocus.com
MiMedx Group Q2 Earnings Call Highlights

MiMedx Group (NASDAQ:MDXG) said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx’s second-quarter results, which showed sequential improvement in its wound-care busines

MarketBeat
MiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance Cut
Simply Wall St.
How The MiMedx Group (MDXG) Story Is Shifting As Analysts Rework Price Targets
Simply Wall St.